Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression Article (Faculty180)

cited authors

  • Lee, Soo Ok; Chun, Jae Yeon; Nadiminty, Nagalakshmi; Lou, Wei; Gao, Allen C


  • Interleukin-6 (IL-6) has been implicated in the modulation of growth and differentiation in many cancers, and is associated with poor prognosis in renal cell carcinoma, ovarian cancer, lymphoma, melanoma, and prostate cancer. The effects of IL-6 on the growth of LNCaP human prostate cancer cells are puzzling with some groups showing growth stimulation, while others showing growth inhibition. In this study, we investigated the discrepancy of the effects of IL-6 on prostate cancer cells.

publication date

  • 2007

published in

start page

  • 764

end page

  • 73


  • 67